IPSCCentury Therapeutics Inc. Common Stock
2.070USD-1.90%Mkt Cap: 374.83M $P/E: —3d ago
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candida…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap374.83M $
Enterprise Value284.73M $
Revenue (TTM)0 $
Gross Profit-78.93M $
Net Income (TTM)-9.58M $
Revenue/Share0.0000 USD
Last Price2.070 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees78
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.46
PEG—
EV/EBITDA-2.99
EV/Revenue—
P/SInfinity
P/B1.57
EPS (TTM)-0.89
EPS (Forward)-0.45
52W Range
0.435063% of range3.040
52W High3.040 USD
52W Low0.4350 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-8.78%
ROE-6.03%
ROA-4.28%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-103.88M $
CapEx (TTM)848.00K $
FCF Margin—
FCF Yield-13.45%
Net Debt-81.05M $
Net Debt/EBITDA0.85
Balance Sheet
Debt/Equity0.27
Current Ratio8.28
Quick Ratio8.04
Book Value/Sh1.287 USD
Cash/Share0.6610 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.750 USD
Upside (mean)+129.5%
Target Range2.000 USD – 8.000 USD
$2.000+129.5% to mean$8.000
# Analysts4
Ownership
Shares Out.181.08M
Float100.88M
Insiders8.15%
Institutions87.40%
Short Interest
Short Ratio25.7d
Short % Float16.66%
Short % Out.16.53%
Shares Short29.82M
Short (prev mo.)23.46M
Technical
SMA 502.172 (-4.7%)
SMA 2001.862 (+11.2%)
Beta1.60
S&P 52W Chg18.16%
Avg Vol (30d)740.17K
Avg Vol (10d)451.78K
Technical Indicators
RSI (14)50.1
MACD-0.0484
MACD Signal-0.0643
MACD Hist.+0.0159
BB Upper2.187 USD
BB Middle2.024 USD
BB Lower1.861 USD
BB Width16.06%
ATR (14)0.1196 USD
Vol Ratio (20d)0.56x